跳至主要内容
临床试验/NCT02948387
NCT02948387Unknown不适用

Antibiotic Prophylaxis for Type II and III Open Fractures: a Retrospective Chart Review

Olayemi Osiyemi MD1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年11月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
50
试验地点
1
主要终点
Rate of fracture site infections

研究概览

简要总结

Determine if antibiotic prophylaxis with intravenous cephalosporin and aminoglycoside in patients with Type II and II open fractures is safe and effective.

详细描述

  1. Determine the safety and efficacy of antibiotic prophylaxis in type II and II open fractures when using IV Cephalosporin and aminoglycoside.
  2. Identify the incidence of acute kidney injury.
  3. Identify the type and number of associated infections
  4. Identify the antibiotic resistance profile noted
  5. Identify any secondary infections at sites other than the fracture site

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female >= 18 years old
  • Patients are diagnosed with a Type II or III open fracture

排除标准

  • Prior to treatment, report of an allergy to beta-lactam or aminoglycoside antibiotics
  • pregnancy
  • did not receive 72 hours of IV antibiotic prophylaxis with 1st or 2nd generation cephalosporin and either gentamicin or tobramycin
  • receiving ongoing inpatient care

结局指标

主要结局

Rate of fracture site infections

时间窗: 30 days

number of infections

次要结局

  • Incidence of acute renal injury(30 days)
  • number of secondary infections at site other than fracture sites(30 days)
  • type of bacteria infection(30 days)
  • resistance trend in patients with infections(30 days)

研究者

发起方
Olayemi Osiyemi MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Olayemi Osiyemi MD

President

Triple O Research Institute PA

研究点 (1)

Loading locations...

相似试验